Interested in stem cell developments.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree, rocky. I am hoping a couple of years, maybe a little longer. Gastro, I note, has further defined his sense of it to "2-5 years" which certainly is reasonable. I was initially reacting to the post of:
"Yes and they say years before commercialization?"
Those in the media who have said something like that and further defined it often said "10-15 years" and a lot of them even said "decades." I was taking issue with my sense of that as the prevailing position of the media.
I agree with your statement of "a couple years" and Gastro's follow-up statement of "2-5 years."
"Yes and they say years before commercialization?"
As you know, Gastro, this is nonsense.
Another good write-up:
Stem Cell Therapy Safe in Macular Degeneration
http://www.medpagetoday.com/Ophthalmology/
"did they seriously sy they destroyed the embryos on CNN ? ……. does anyone knoww if CNN was misinformed or if they did destroy the embryo for this study ?"
The evangelicals, etc., probably intentionally, always get this wrong but the media usually seems to mangle it as well. The RPE cells currently being used were derived from the ACTC MA09 hESC line. ACTC in a series of ten separate experiments demonstrated that hES cells can be derived from single blastomeres without the destruction of the embryo. Although the procedure for creating the new stem cell lines did not entail destruction of the embryo, it was decided, well after the studies were completed, to discard (ie destroy) the embryo since it had been donated for research and was never going to be used. Again, many out there like to get this wrong and others, such as many in the media, are still under the spell of the piles of Bush Administration propaganda that was aimed misrepresenting especially hESC stem cell issues. Here is a summary of the MA09 derivation and the url for the full paper:
Human embryonic stem cell lines derived from single blastomeres
Irina Klimanskaya1*, Young Chung1*, Sandy Becker1, Shi-Jiang Lu1 & Robert Lanza1
The derivation of human embryonic stem (hES) cells currently requires the destruction of ex utero embryos1–4. A previous study in mice indicates that it might be possible to generate embryonic stem (ES) cells using a single-cell biopsy similar to that used in preimplantation genetic diagnosis (PGD), which does not inter- fere with the embryo’s developmental potential5. By growing the single blastomere overnight, the resulting cells could be used for both genetic testing and stem cell derivation without affecting the clinical outcome of the procedure. Here we report a series of ten separate experiments demonstrating that hES cells can be derived from single blastomeres. In this proof-of-principle study, multiple biopsies were taken from each embryo using micromanipulation techniques and none of the biopsied embryos were allowed to develop in culture. Nineteen ES-cell-like outgrowths and two stable hES cell lines were obtained. The latter hES cell lines main- tained undifferentiated proliferation for more than eight months, and showed normal karyotype and expression of markers of pluri- potency, including Oct-4, SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, nanog and alkaline phosphatase. These cells retained the potential to form derivatives of all three embryonic germ layers both in vitro and in teratomas. The ability to create new stem cell lines and therapies without destroying embryos would address the ethical concerns of many, and allow the generation of matched tissue for children and siblings born from transferred PGD embryos.
http://cord.rutgers.edu/stemcellcourse/documents/hESC_from_PGD_Nature_07.pdf
"No more Jobs. No more Cash NO MORE Hope."
Right, Alpha, and even the Bush in the hand turned out to be barren.
Gastro, I do have to say to you and a few others it strikes me as quite ridiculous to think that Rabin or anyone at ACTC spends any time at all actively trying to manipulate the ACTC stock price. There may be some manipulation of the stock price but not by anyone at ACTC. Among other things, I don't think they could do it very easily so it would most likely not be very productive and I do think they have much better things to do which will turn out to be much more productive and which over time will have the desired effect on the stock price without direct manipulation of stock trading.
Here's the scary part:
<<<<<<<<<<<<<<<
..... The NIH appealed the preliminary injunction to the same appeals court, but to a different randomly-assigned three-judge panel. That panel ruled in favor of the NIH, by a two-to-one vote, vacating the preliminary injunction and once again sending the case back to the district court.
Finally, in September of 2011, the district court ruled against Sherley and in favor of the NIH.
What’s different this time?
Sherley’s appeal before the appeals court will be heard by yet another randomly-selected three-judge panel, the third to hear the case. This panel includes Karen L. Henderson, who was the dissenting vote in favor of Sherley when the injunction was vacated, and Janice R. Brown, who was on the first panel that unanimously concluded that Sherley had standing. ....
>>>>>>>
Embryonic stem cell research challenged, again
Sherley continues stem cell debate with an appeal to a panel of judges for the third time
http://tech.mit.edu/V131/N61/stemcells.html
"Why would it hold with 300 million shares
being dumped on the market?
Obviously these investors are oblivious to that."
Generally in this kind of investment virtually all of these companies would dump immediately if they are in position to gain any kind of profit. At this point, however, it seems likely that a lot of these companies have come back and gotten interested in the current lawsuits because they suddenly realize the potential of ACTC. It is possible this is a rare instance in which some of these companies may hold onto a lot of the stock for some period of time as opposed to the way they usually handle these investments.
In addition to some improvement of vision from some revival of marginal photoreceptors (most likely only a small number) there is another possibility for some improved vision mentioned by Dr. Schwartz which is that replenishing the RPE layer can provide better absorption of stray light which can allow for better image resolution.
You are right, interstate. A few marginal rods and cones could be revived but rods and cones cannot be regenerated by refurbishing the RPE layer. I do think ddls wants to confuse the issue by raising expectations beyond the real possibilites.
ACTC trials reported showing cell migration and engraftment:
"Advanced Cell Technology is transforming stem cells into retinal pigment epithelial cells to treat macular degeneration. Trials are showing cell migration and engraftment."
http://ebdgroup.com/partneringnews/2012/01/the-exciting-state-of-regenerative-medicine/
I should add that this was a great find by a78scorpio25 on the Yahoo board.
"....Does anyone have any understanding of how much time it would take to determine if rejection or acceptance has occurred?..."
With the techniques Schwartz, Lanza and Rabin have already discussed re the ability to now see non-invasively into the eye in incredible detail and in virtually real time, I am quite certain the results on the first two patients are basically in with quite active monitoring continuing. I think Schwartz, Lanza and the ACTC and UCLA teams know a tremendous amount already. As Rabin has said they are carefully pursuing the correct venue to set out the findings.
New Lanza Tweet provides emphasis re Rabin blog:
Tweet: "the additional waiting time will be measured only in weeks, not months @actcbiotech Clinical Trials, Results, & Timing
I was wondering also, Jmasdoc, as I haven't received mine either.
You are right, here, Gastro. Certainly someone, or more, seems to know something the rest of us don't. And, no doubt, if the current buyers turn out to be very prescient beneficiaries, the SEC will never see or hear a thing about them either.
Through the Wormhole is much more likely to focus on Biocentrism than ACTC or RPE. I would be very happy to see a tv program have a big positive impact but I doubt it will. And don't forget the Barbara Walter's special!...which was counterproductive (though, truthfully, that was a manipulated negative outcome, but alas a tv program not accompanied by very specific news is not going to do much imo).
"....getting featured on some major tv program wouldn't hurt either. .."
Been there, done that.
"I think this rise in the PPS Humbles everyone as it goes to show no one knows didly Squat. Including all the DD Guru's out there."
How so, Gastro?
"Many are mad because they did not buy more which would make them traders and not longs."
How so, Gastro?
Do ya think somebody knows something?
"I do remember that certain shareholders (basically Rabin/Lanza I believe) lent ACT shares to cover the shortfall of shares needed to comply with the shares awarded (and issued) to Alpha, Cranshire and Black Mountain cases ordered them to give those companies at trial, so I would assume that those ~50 million additional shares referenced in that post would include the shares that need to be issued to repay management the shares they lent the company so they would not go into default on the judgments..."
Spetty, do you have any evidence of such lending of shares. That was asserted on one message board but later was fairly convincingly refuted as a convenient assumption that was not not valid.
You are right again, Gastro. The good Doctor Langer is the Jack of all trades and Master of All of Them.
Gastro, I think it is time to stop citing your daughter and her very limited biotech experience. Many of us here know a lot more about this stuff than your daughter does.
Anthony Atala: Printing A Human Kidney
http://www.huffingtonpost.com/2011/12/20...
[Atala is a colleague of Lanza at Wake Forest]
"I cannot believe anyone is buying shares right now? Either they are traders , have more money than Brains or are complete IDIOTS."
Gastro, you sorely tempt me to see that as a buy signal for the rest of us.
Gastro, if there is Insider Trading going on here let's hope it is by members of our U.S. Congress. It would be a very good sign, unfortunately, since they can do it legally and are not reticent to get in on a very good thing.
Gastro, do you really expect us to believe you didn't really mean that first version? The first version was, in fact, better.
Gastro, I thought you said only one guy.
"Just had someone from the phillipines use my credit card and the fraud department stopped the transaction. Wall street and many companies need a fraud department."
Gastro, Wall Street is its very own Fraud Department.
Overlooked Clues In The Hottest Names Of Biotech
http://seekingalpha.com/article/313928-overlooked-clues-in-the-hottest-names-of-biotech?source=yahoo
There are no nuns in the trial or, as far as we know, even scheduled to be in any of the trials at this time. There are two nuns with AMD who told Dr. Schwartz, who is leading the trials at UCLA Jules Stein Eye Institute, that their religious beliefs would not stop them from being in the trials and they would do so if they had the chance to be.
Advanced Cell Technology (ACTC) Can Now Look Forward Following Lawsuit Resolution
http://marketplayground.com/2011/12/14/advanced-cell-technology-actc-can-now-look-forward-following-lawsuit-resolution/
Gastro, let us know right away if an ACTC chicken, rat, or mouse (especially the second one) starts raiding your bird seed.
I'm just wondering if Gastro works for free.
ACT Announces Two New Appointments to Board of Directors
http://finance.yahoo.com/news/ACT-Announces-Two-New-bw-3697549106.html?x=0
Scalable amounts of liver and pancreas precursor cells created using new stem cell production method
Technique should help research into pre-clinical and clinical evaluation of cells
http://www.eurekalert.org/pub_releases/2011-12/w-sao120211.php
In all honesty, fairview, I think you may have overstated the case for Gastro.
The great "Barnacle of Delphi" has spoken.